Celestica’s SWOT analysis: stock gains momentum on AI growth By Investing.com

Celestica raised fiscal 2026 guidance by about $1 billion after delivering Q4 and full-year 2025 results above expectations, with revenue up 37% over the last twelve months and analysts revising earnings higher. The company plans a fivefold increase in 2026 capex to support AI infrastructure and hyperscale cloud demand, while analysts have lifted targets to as high as $391.00. The key risk is execution: profitability remains below some peers and the aggressive expansion increases capital intensity and customer-concentration exposure.

Analysis

CLS is becoming a leveraged proxy on the next leg of AI infrastructure spend, but the market is likely underestimating how much of the upside is already embedded in its capex plan. A fivefold buildout only works if hyperscale customers keep pulling forward orders; that creates a near-term squeeze on peers with less flexible capacity and stronger balance sheets, because capacity-constrained EMS names can price more aggressively while CLS is still in ramp mode.

The second-order winner is less obvious: suppliers of automation, test equipment, and industrial real estate tied to electronics manufacturing should see a multi-quarter demand tail as CLS and peers race to add throughput. The loser is any competitor competing primarily on idle capacity — once the AI cycle turns into a capacity race, scale and execution matter more than headline margin, and smaller players can get boxed out of new sockets or forced into lower-return pricing.

The key risk is not demand collapse in the next few weeks; it is a 6-12 month normalization of hyperscaler capex growth after the current surge, right as CLS is booking depreciation and working capital from new assets. If AI switching demand is real but less broad-based than expected, the stock can de-rate fast because the current multiple implies both high growth and sustained margin discipline. The market is still treating this as a clean growth story, but the gap between reported revenue growth and ultimate free-cash-flow conversion will be the battleground.

Contrarian read: the consensus is probably right on direction but wrong on durability. The stock looks less attractive as a straight long after this rerating; the better expression is to own the beneficiaries of the capex wave that have not rerated yet, or to buy CLS on pullbacks only if management proves the 2026 spend is translating into backlog conversion rather than just capacity accumulation.

Key Decisions for Investors

• Avoid adding CLS at current levels; wait for a 10-15% drawdown or a post-earnings reset before initiating, since the stock is pricing in continued upward guidance revisions over the next 2-3 quarters.
• Pair trade: long SOXX / short CLS for 3-6 months if you expect AI infrastructure spend to broaden out but CLS valuation to mean-revert faster than the semiconductor equipment complex.
• Long ETN or AMAT on a 6-9 month horizon as indirect beneficiaries of the electronics capacity buildout; they capture the capex cycle with less customer-concentration risk than CLS.
• If already long CLS, finance upside with a covered call into the next earnings print; the skew favors monetizing premium because the stock’s path dependence is now tied to execution on capex, not just demand.
• For tactical exposure, buy a call spread in CLS expiring after the next two earnings cycles; upside exists if backlog converts cleanly, but the defined risk is preferable given execution and de-rating risk.